计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| G413317-1mg |
1mg |
现货 ![]() |
| |
| G413317-5mg |
5mg |
现货 ![]() |
| |
| G413317-10mg |
10mg |
现货 ![]() |
| |
| G413317-25mg |
25mg |
现货 ![]() |
| |
| G413317-50mg |
50mg |
现货 ![]() |
| |
| G413317-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | BDBM50573891 | A-1282576 | (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclop | (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]car |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Glecaprevir |
| 生化机理 | Glecaprevir 是一种针对病毒 RNA 复制的丙型肝炎病毒(HCV)非结构(NS)蛋白 3/4A 蛋白酶抑制剂。它对临床分离的 1a、1b、2a、2b、3a、4a、5a 和 6a 型 HCV 基因型的 IC50 值介于 3.5 到 11.3 nM 之间。 |
| 储存温度 | -20°C储存,充氩 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 丙型肝炎病毒丝氨酸蛋白酶、NS3/NS4A 抑制剂 |
| 产品介绍 |
Information Glecaprevir Glecaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that targets the the viral RNA replication. It displays IC50 values ranging from 3.5 to 11.3 nM for clinical isolates of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a. |
| 纯度 | ≥98% |
| ALogP | 3.746 |
|---|---|
| hba_count | 11 |
| HBD Count | 3 |
| Rotatable Bond | 7 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | (1R,14E,18R,22R,26S,29S)-26-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide |
| INCHI | 1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1 |
| InChi Key | MLSQGNCUYAMAHD-ITNVBOSISA-N |
| Smiles | CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C |
| Isomeric SMILES | CC1(CC1)S(=O)(=O)NC(=O)[C@]2(C[C@H]2C(F)F)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)O[C@@H]5CCC[C@H]5OC/C=C/C(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C |
| 分子量 | 838.87 |
| Reaxy-Rn | 40672945 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=40672945&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 100 mg/mL (119.2 mM); Ethanol: 100 mg/mL (119.2 mM); Water: Insoluble; |
|---|---|
| 敏感性 | 易吸潮 |
| DMSO(mg / mL) Max Solubility | 100 |
| DMSO(mM) Max Solubility | 119.207982166486 |
| Water(mg / mL) Max Solubility | -1 |
| 分子量 | 838.900 g/mol |
| XLogP3 | 4.600 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 15 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 838.298 Da |
| 单同位素质量Monoisotopic Mass | 838.298 Da |
| 拓扑极表面积Topological Polar Surface Area | 204.000 Ų |
| 重原子数Heavy Atom Count | 58 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1760.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 7 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 1 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 1 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 |
| 1. Lawitz EJ, O'Riordan WD, Asatryan A, Freilich BL, Box TD, Overcash JS, Lovell S, Ng TI, Liu W, Campbell A et al.. (2015) Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.. Antimicrob Agents Chemother, 60 (3): (1546-55). [PMID:26711747] |